Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31556032 | 0.94 | CA12 (0.41) | CA12CA2CA14CA1MEN1 | |
| SCHEMBL8861950 | 0.88 | SLC1A1 (0.42) | CA12CA2CA14CA1MEN1 | |
| SCHEMBL31407405 | 0.88 | SLC1A1 (0.42) | CA12CA2CA14CA1MEN1 | |
| SCHEMBL20095123 | 0.88 | CA12 (0.38) | CA12CA2CA14CA1MEN1 | |
| SCHEMBL27041570 | 0.86 | CA14 (0.42) | CA12CA2CA14CA1MEN1 | |
| SCHEMBL2390690 | 0.86 | CA14 (0.42) | CA12CA2CA14CA1MEN1 | |
| SCHEMBL15418769 | 0.86 | CA14 (0.42) | CA12CA2CA14CA1MEN1 | |
| SCHEMBL21510658 | 0.85 | CA12 (0.40) | CA12CA2CA14CA1MEN1 | |
| SCHEMBL26181356 | 0.85 | CA12 (0.40) | CA12CA2CA14CA1MEN1 | |
| SCHEMBL20089212 | 0.84 | MMP13 (0.36) | CA12CA2CA14CA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20180111914-A1 | WATER-SOLUBLE PRODRUGS | BOSTON BIOMEDICAL, INC. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111914-A1 | WATER-SOLUBLE PRODRUGS | NR0B2, NR0B1, AVPR1B | CA12 521/4885CA2 811/4885CA14 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.